The fundamental architecture of the software-as-a-service (SaaS) economy is facing a potential inflection point. For years, the “per-seat” subscription model—charging a monthly or annual fee for every single user who logs into a platform—has been the gold standard for predictable revenue. Still, the emergence of autonomous AI capabilities is beginning to challenge the necessity of the user interface itself.
Anthropic recently introduced Managed Agents, a service designed to run autonomous AI workflows for businesses. Unlike traditional software, which requires a human to navigate a dashboard to complete a task, these agents can interact directly with data and systems to execute complex processes. This shift moves the value proposition from the software interface to the outcome of the work, potentially rendering the traditional seat-based subscription obsolete for certain enterprise functions.
This evolution creates a specific set of risks for Doximity (NYSE:DOCS), a digital platform that serves as a critical hub for U.S. Clinicians. By combining professional networking, telehealth tools, and workflow software, Doximity has built a powerful ecosystem. Yet, as large AI providers offer plug-and-play infrastructure for automation, the question arises: could Anthropic Managed Agents pressure the Doximity SaaS business model by automating the very workflows that currently retain clinicians tied to a specific software seat?
For investors, the tension lies in where the value truly resides. If a clinician’s primary need is the efficient movement of data or the automation of administrative tasks, a generic AI orchestrator may eventually be more attractive than a specialized software suite. The risk is not necessarily a sudden drop in users, but a fundamental change in how customers view pricing, integration, and the necessity of a proprietary interface.
The Shift from User Interfaces to AI Orchestration
To understand the threat, one must gaze at the difference between a tool and an agent. A tool, like the workflow software provided by Doximity, requires a human operator to drive it. The company charges for the privilege of accessing that tool. An agent, however, is designed to achieve a goal autonomously. If an enterprise can spin up an AI agent to handle clinician coordination or data retrieval directly on top of its own systems, the need for a third-party “seat” diminishes.
Doximity’s strength has always been its high density of medical professionals, creating a network effect that is difficult to replicate. However, the “workflow” portion of their business is more vulnerable. When AI can handle the orchestration of tasks, the “interface” becomes a commodity. If the value is in the data and the result, the software layer—the part that generates the subscription fee—becomes a friction point rather than a feature.
Who is Affected and How?
The impact of this transition is felt across three primary stakeholder groups:
- Enterprise Customers: Life sciences companies and healthcare systems may shift from paying for hundreds of individual licenses to paying for a set of autonomous agents that handle the same volume of work more efficiently.
- Clinicians: The finish-user experience may shift from logging into a platform to interacting with an AI layer that pulls information from various sources, reducing “app fatigue.”
- SaaS Providers: Companies like Doximity must determine if they can pivot their pricing models from “per-user” to “per-outcome” or “per-task” to maintain margins.
Analyzing Doximity’s Market Position
Despite the looming pressure from AI agents, Doximity’s current financial metrics suggest a company that is viewed by many analysts as undervalued. The stock has experienced recent volatility, with a 30-day return showing a decline of approximately 14.6%. However, this price action stands in contrast to long-term analyst targets.
| Metric | Current Value / Status | Context |
|---|---|---|
| Current Price | US$21.05 | Market price as of recent reporting |
| Analyst Price Target | US$39.05 | Trading ~46% below target |
| Fair Value Estimate | -57.8% | Trading below estimated fair value |
| Recent Momentum | Negative | 14.6% decline over 30 days |
The discrepancy between the current trading price and the analyst targets suggests that the market may already be pricing in some of the uncertainty surrounding AI disruption, or that the company’s intrinsic value is not being fully recognized. The key risk remains whether generic AI orchestration reduces the reliance on Doximity’s specific interface, which could erode the company’s ability to defend its subscription economics.
The Path Forward: Essentiality vs. Utility
For Doximity to withstand the pressure from services like Anthropic’s Managed Agents, it must move beyond being a utility and remain a destination. There is a fundamental difference between a tool that helps you do a task and a network where you travel to find professional community and verified peer-to-peer interaction.
If Doximity can integrate its own AI capabilities—effectively becoming the “agent” for the clinician rather than being replaced by one—it can maintain its essential status. The strategy will likely involve deeper integration into clinician workflows, moving away from a simple portal and toward an intelligent layer that manages the professional life of a physician.
Investors should monitor three specific indicators in the coming quarters:
- Pricing Shifts: Any move away from seat-based pricing toward usage-based or outcome-based models.
- AI Partnership/Releases: The introduction of native autonomous agents within the Doximity ecosystem.
- Churn Rates: Whether enterprise life sciences customers initiate reducing seat counts in favor of external AI automation.
Disclaimer: This article is provided for informational purposes only and does not constitute financial advice. Investing in equities involves risk, and past performance is not indicative of future results.
The next critical checkpoint for Doximity will be its upcoming quarterly earnings filings, where management is expected to address AI integration strategies and the stability of their enterprise subscription base. These reports will provide the first concrete evidence of whether the “agentic” shift is beginning to impact their top line.
We would love to hear your thoughts on the shift toward AI agents in the SaaS space. Do you believe the “per-seat” model is dead? Share your perspective in the comments below.
